| Somatotropin deficiency
Nutropin AQ vs Sogroya
Side-by-side clinical, coverage, and cost comparison for somatotropin deficiency.Deep comparison between: Nutropin Aq Nuspin 10 vs Sogroya with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSogroya has a higher rate of injection site reactions vs Nutropin Aq Nuspin 10 based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Sogroya but not Nutropin Aq Nuspin 10, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Nutropin Aq Nuspin 10
Sogroya
At A Glance
SC injection
Daily
Recombinant human growth hormone
SC injection
Once weekly
Growth hormone analog
Indications
- Somatotropin deficiency
- Turner Syndrome
- Chronic Kidney Diseases
- Somatotropin deficiency
- Noonan Syndrome
Dosing
Somatotropin deficiency (pediatric) Up to 0.3 mg/kg/week divided into daily SC injections; pubertal patients may use up to 0.7 mg/kg/week divided daily.
Somatotropin deficiency (adult) Weight-based: starting dose up to 0.006 mg/kg/day SC, max 0.025 mg/kg/day (age <=35 years) or 0.0125 mg/kg/day (age >35 years); or non-weight-based: starting dose approximately 0.2 mg/day SC with gradual titration every 1-2 months.
Chronic Kidney Diseases Up to 0.35 mg/kg/week divided into daily SC injections; therapy may continue until renal transplantation.
Turner Syndrome Up to 0.375 mg/kg/week divided into equal doses 3 to 7 times per week by SC injection.
Somatotropin deficiency (pediatric) 0.16 mg/kg SC once weekly for treatment-naive patients and those switching from daily somatropin.
Noonan Syndrome, SGA, ISS 0.24 mg/kg SC once weekly for treatment-naive patients and those switching from daily somatropin.
Somatotropin deficiency (adult) Initiate 1.5 mg SC once weekly; titrate every 2-4 weeks by 0.5-1.5 mg to desired response; maximum 8 mg once weekly.
Contraindications
- Acute critical illness due to complications following open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
- Prader-Willi syndrome in children with severe obesity, history of upper airway obstruction or sleep apnea, or severe respiratory impairment
- Active malignancy
- Known hypersensitivity to somatropin or any excipient
- Active proliferative or severe non-proliferative diabetic retinopathy
- Closed epiphysis (for growth promotion in pediatric patients)
- Acute critical illness after open-heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
- Hypersensitivity to somapacitan-beco or any excipient
- Pediatric patients with closed epiphyses
- Active malignancy
- Active proliferative or severe non-proliferative diabetic retinopathy
- Pediatric patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment
Adverse Reactions
Most common Edema or peripheral edema (adults with GHD), arthralgias (adults with GHD), otitis media and ear disorders (Turner syndrome), injection site discomfort (pediatric GHD)
Serious Intracranial hypertension, glucose intolerance, slipped capital femoral epiphysis, scoliosis progression, leukemia, pancreatitis, severe hypersensitivity reactions, hypothyroidism, hypoadrenalism, lipoatrophy
Postmarketing Anaphylaxis, angioedema, leukemia, gynecomastia (children), pancreatitis, slipped capital femoral epiphysis, osteonecrosis
Most common (>=5%) Nasopharyngitis, respiratory tract infection, pyrexia, headache, pain in extremity, injection site reaction, diarrhea, vomiting, cough, ear infection
Serious Increased mortality in acute critical illness, severe hypersensitivity, neoplasm risk, glucose intolerance and diabetes mellitus, intracranial hypertension, fluid retention, hypoadrenalism, hypothyroidism, slipped capital femoral epiphysis, scoliosis progression, pancreatitis, lipohypertrophy/lipoatrophy, sudden death in Prader-Willi syndrome patients
Postmarketing Osteonecrosis in pediatric patients
Pharmacology
Somatropin is a recombinant human growth hormone that binds to dimeric GH receptors on target cell membranes, triggering intracellular signal transduction; pharmacodynamic effects include skeletal growth and protein synthesis mediated via IGF-1, as well as direct effects such as lipolysis.
Somapacitan-beco is a human growth hormone (hGH) analog that binds to a dimeric GH receptor in the cell membrane of target cells, triggering intracellular signal transduction and pharmacodynamic effects mediated both directly and through IGF-1 produced in the liver.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Nutropin Aq Nuspin 10
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
Sogroya
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Nutropin Aq Nuspin 10
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Sogroya
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Nutropin Aq Nuspin 10
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Sogroya
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Nutropin Aq Nuspin 10.
No savings programs available for Sogroya.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Nutropin Aq Nuspin 10View full Nutropin Aq Nuspin 10 profile
SogroyaView full Sogroya profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.